Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Accenture
Healthtrust
Daiichi Sankyo
Federal Trade Commission
Boehringer Ingelheim
Moodys
Colorcon
Harvard Business School

Generated: May 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,790,641

« Back to Dashboard

Which drugs does patent 8,790,641 protect, and when does it expire?

Patent 8,790,641 protects ELELYSO and is included in one NDA.

This patent has seventy-four patent family members in twenty-five countries.
Summary for Patent: 8,790,641
Title:Production of high mannose proteins in plant culture and therapeutic uses thereof
Abstract: A device, system and method for producing glycosylated proteins in plant culture, particularly proteins having a high mannose glycosylation, while targeting such proteins with an ER signal and/or by-passing the Golgi. The invention further relates to vectors and methods for expression and production of enzymatically active high mannose lysosomal enzymes using transgenic plant root, particularly carrot cells. More particularly, the invention relates to host cells, particularly transgenic suspended carrot cells, vectors and methods for high yield expression and production of biologically active high mannose Glucocerebrosidase (GCD). The invention further provides for compositions and methods for the treatment of lysosomal storage diseases.
Inventor(s): Shaaltiel; Yoseph (Kibbutz HaSolelim-Doar-Na HaMovil, IL), Baum; Gideon (D.N. Upper Galilee, IL), Bartfeld; Daniel (Moran-Doar-Na Bikat Beit HaKerem, IL), Hashmueli; Sharon (Ramot-Naftali, IL), Lewkowicz; Ayala (Kfar-Vradim, IL)
Assignee: Protalix Ltd. (Carmiel, IL)
Application Number:12/385,894
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 8,790,641

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Pfizer ELELYSO taliglucerase alfa POWDER;IV (INFUSION) 022458-001 May 1, 2012 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial A METHOD OF TREATING GAUCHER'S DISEASE ➤ Try a Free Trial
Pfizer ELELYSO taliglucerase alfa POWDER;IV (INFUSION) 022458-001 May 1, 2012 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial A METHOD OF CATALYZING THE HYDROLYSIS OF GLUCOCEREBROSIDE TO GLUCOSE AND CERAMIDE. ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,790,641

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Israel155588Apr 27, 2003

Non-Orange Book US Patents Family Members for Patent 8,790,641

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,227,230 Human lysosomal proteins from plant cell culture ➤ Try a Free Trial
6,391,638 Cell/tissue culturing device and method ➤ Try a Free Trial
9,220,737 Plant cell culture expressing human lysosomal proteins and uses thereof ➤ Try a Free Trial
8,741,620 Human lysosomal proteins from plant cell culture ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 8,790,641

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 231912 ➤ Try a Free Trial
Australia 2004234635 ➤ Try a Free Trial
Australia 2005214181 ➤ Try a Free Trial
Australia 2008243744 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Cipla
Dow
Fuji
Covington
Johnson and Johnson
Fish and Richardson
Queensland Health
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.